摘要
目的:评价拉莫三嗪对难治性癫痫的治疗作用和安全性。方法:难治性癫痫病人76例治疗前3mo开始填写发作的逐日志,完成后随机分成单盲、安慰剂对照(n=44)与双盲、交叉、安慰剂对照(n=32)2组,保持原用抗痫药不变,按50~400mg/d(未用丙戊酸者)或25~200mg/d(用丙戊酸者),qod,qn或bid加用拉莫三嗪,对照组用同等剂量的维生素C,3mo为一个疗程。结果:拉莫三嗪有效率为56%,不良反应较轻。结论:拉莫三嗪治疗难治性癫痫是有效和安全的。
AIM: To evaluate the therapeutic effect and safety of lamotrigine. METHODS: The trial was designed in ramdomized, single-blind, placebo-controlled or double-blind, cross-over method. Seventy-six refractory epileptic patients were divided into 2 groups. In group I, 22 patients (M 8, F 14, age 30±s 9 a) received lamotrigine 50-400 mg/d for the patients without valproate or 25-200 mg/d for the patients with valproate, po, qod, qn, or bid for 3 mo. Other similar 22 patients with epilepsy (M 8, F 14, age 31±9 a) received palcebo (ascorbic acid) 25-400 mg/d qod, qn, or bid for 3 mo. In group II, 16 patients (M 3, F 13, age 29±10 a) received lamotrigine for 3 mo, and after 2 wk, followed by placebo for 3 mo. Other 16 patients (M 7, F 9, age 31±11 a) were treated with placebo for 3 mo and after 2 wk followed by lamotrigine for 3 mo. Group II was similar to group I in dosages and adminstration. RESULTS: The total effective and adverse rates of lamotrigine were 56% and 15%, respectively. CONCLUSION: Lamotrigine is effective in reducing seizure frequency in patients with refractory seizures. Adverse reactions are mild.
出处
《新药与临床》
CSCD
北大核心
1997年第5期260-262,共3页
关键词
抗惊厥药
拉莫三嗪
癫药
药物疗法
anticonvulsants
lamotrigine
tonic-clonic epilepsy